Get the Stockscreener App
59.89
4.68%
2.68
After Hours:
59.95
0.06
+0.10%
Kymera Therapeutics Inc stock is traded at $59.89, with a volume of 813.20K.
It is up +4.68% in the last 24 hours and up +27.45% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$57.21
Open:
$57.89
24h Volume:
813.20K
Relative Volume:
1.13
Market Cap:
$4.28B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-19.32
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
+4.07%
1M Performance:
+27.45%
6M Performance:
+148.30%
1Y Performance:
+33.03%
1-Day Range:
$56.58
$60.00
1-Week Range:
$55.99
$60.00
52-Week Range:
$19.45
$60.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
59.89 | 4.09B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics stock hits 52-week high at 59.03 USD - Investing.com India
What earnings revisions data tells us about Kymera Therapeutics Inc.2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
Is Kymera Therapeutics Inc. stock attractive for ETFsPortfolio Performance Report & Reliable Entry Point Trade Alerts - newser.com
Advanced analytics toolkit walkthrough for Kymera Therapeutics Inc.July 2025 Selloffs & AI Enhanced Trading Alerts - newser.com
What’s the recovery path for long term holders of Kymera Therapeutics Inc.Weekly Market Outlook & Smart Investment Allocation Tips - newser.com
Will Kymera Therapeutics Inc. see short term momentumJuly 2025 Market Mood & Safe Entry Momentum Tips - newser.com
Custom strategy builders for tracking Kymera Therapeutics Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - newser.com
Kymera Therapeutics Inc Stock Analysis and ForecastSupport and Resistance Levels & Free Stock Market Mentorship Programs - earlytimes.in
Full technical analysis of Kymera Therapeutics Inc. stock2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Kymera Therapeutics Inc. stock chart pattern explainedFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Ranking Kymera Therapeutics Inc. among high performing stocks via toolsWeekly Market Report & Risk Controlled Swing Alerts - newser.com
Should you hold or exit Kymera Therapeutics Inc. nowJuly 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Top chart patterns to watch in Kymera Therapeutics Inc.Market Trend Review & Community Verified Watchlist Alerts - newser.com
Kymera Therapeutics Hits New 52-Week High of $59.00, Up 69% - Markets Mojo
Analyzing net buyer seller activity in Kymera Therapeutics Inc.Sell Signal & High Yield Stock Recommendations - newser.com
Will Kymera Therapeutics Inc. stock maintain momentum in 20252025 Market WrapUp & Safe Capital Allocation Plans - newser.com
Tools to monitor Kymera Therapeutics Inc. recovery probabilityMarket Growth Summary & Capital Protection Trading Alerts - newser.com
Keudell Morrison Wealth Management Invests $334,000 in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics stock hits 52-week high at $58.97 By Investing.com - Investing.com Nigeria
Kymera Therapeutics stock hits 52-week high at $58.97 - Investing.com
What analysts say about Kymera Therapeutics Inc stockGlobal Trade Effects & Low Risk Capital Growth Plans - earlytimes.in
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $59.95 - Defense World
Real time pattern detection on Kymera Therapeutics Inc. stockMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Given New $68.00 Price Target at Truist Financial - Defense World
Oppenheimer Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Therapeutics Hits New 52-Week High of $58.93, Up 65.21% - Markets Mojo
Is Codere Online Luxembourg SA a good long term investmentVolume Weighted Average Price & Learn the Basics of Investing in 5 Days - earlytimes.in
Oppenheimer Raises Price Target for Kymera Therapeutics (KYMR) t - GuruFocus
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline - Nasdaq
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $63 - 富途牛牛
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
Truist Securities raises Kymera Therapeutics stock price target to $68 on KT-621 potential - Investing.com Canada
Truist Securities Boosts KYMR Price Target by Over 28% | KYMR Stock News - GuruFocus
Truist Financial Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $68.00 - MarketBeat
Truist Raises Price Target on Kymera Therapeutics to $68 From $53, Keeps Buy Rating - MarketScreener
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $68 - 富途牛牛
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Published on: 2025-09-30 02:20:06 - newser.com
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):